SG Americas Securities LLC cut its stake in shares of Axonics, Inc. (NASDAQ:AXNX – Get Rating) by 93.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,500 shares of the company’s stock after selling 89,256 shares during the quarter. SG Americas Securities LLC’s holdings in Axonics were worth $458,000 at the end of the most recent reporting period.
→ The Next Big Crisis Is Here (From Porter & Company)
Other large investors have also modified their holdings of the company. Wipfli Financial Advisors LLC acquired a new position in Axonics during the third quarter valued at $28,000. Captrust Financial Advisors grew its stake in Axonics by 64.6% during the 1st quarter. Captrust Financial Advisors now owns 706 shares of the company’s stock valued at $44,000 after acquiring an additional 277 shares in the last quarter. Strs Ohio purchased a new position in Axonics during the 2nd quarter valued at about $45,000. Point72 Hong Kong Ltd purchased a new position in Axonics during the 2nd quarter valued at about $50,000. Finally, Nisa Investment Advisors LLC grew its stake in Axonics by 14.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,620 shares of the company’s stock valued at $92,000 after acquiring an additional 200 shares in the last quarter. 97.49% of the stock is owned by institutional investors.
Insiders Place Their Bets
In other news, Director Esteban Lopez sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $67.42, for a total transaction of $134,840.00. Following the completion of the transaction, the director now directly owns 3,600 shares in the company, valued at $242,712. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, EVP John Woock sold 30,215 shares of the company’s stock in a transaction that occurred on Tuesday, January 17th. The stock was sold at an average price of $67.34, for a total transaction of $2,034,678.10. Following the completion of the transaction, the executive vice president now directly owns 45,976 shares in the company, valued at $3,096,023.84. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Esteban Lopez sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $67.42, for a total value of $134,840.00. Following the transaction, the director now owns 3,600 shares of the company’s stock, valued at $242,712. The disclosure for this sale can be found here. Insiders sold 108,966 shares of company stock valued at $7,247,046 over the last 90 days. 2.31% of the stock is currently owned by company insiders.
Analysts Set New Price Targets
Several equities analysts have weighed in on the company. Jefferies Financial Group assumed coverage on Axonics in a research note on Wednesday, October 12th. They set a “hold” rating and a $75.00 target price on the stock. Needham & Company LLC cut Axonics from a “buy” rating to a “hold” rating in a research note on Monday, October 10th. Piper Sandler lifted their target price on Axonics from $82.00 to $84.00 and gave the company an “overweight” rating in a research note on Wednesday, October 5th. Truist Financial lowered their price target on Axonics from $90.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, December 20th. Finally, Morgan Stanley lowered their price target on Axonics from $92.00 to $76.00 and set an “overweight” rating for the company in a research note on Friday, January 6th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.11.
Axonics Stock Up 2.2 %
Shares of Axonics stock opened at $61.05 on Thursday. The stock has a market capitalization of $3.02 billion, a P/E ratio of -37.00 and a beta of 0.43. The stock has a 50 day moving average price of $63.30 and a two-hundred day moving average price of $67.10. Axonics, Inc. has a 12-month low of $38.41 and a 12-month high of $79.92.
Axonics (NASDAQ:AXNX – Get Rating) last announced its earnings results on Monday, October 31st. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13. The firm had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $62.98 million. Axonics had a negative return on equity of 15.63% and a negative net margin of 31.35%. The company’s revenue was up 50.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.38) earnings per share. Sell-side analysts anticipate that Axonics, Inc. will post -1.6 earnings per share for the current year.
Axonics Company Profile
Axonics, Inc is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women.
Featured Stories
Want to see what other hedge funds are holding AXNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axonics, Inc. (NASDAQ:AXNX – Get Rating).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Axonics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Axonics wasn’t on the list.
While Axonics currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
